Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received

Centre Francois Baclesse20 enrolled

Overview

The main objective is to detect with TESLA multiparametric 3 MRI, the MRI secondary changes to protontherapy irradiation and to correlate them with TEL mapping, physical dose and biological dose. A model should thus be able to be proposed at the end of the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Benign Brain Tumors Proton Therapy

Interventions

MRI 3 teslaDEVICE

1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months) In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed: * During treatment when half of the prescribed dose has been delivered. * 1 month after the end of the irradiation.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven or highly probable grade I meningiomas, histologically proven grade II meningiomas. * Only meningiomas of the anterior and middle floors of the base of the skull are included. * Indication of proton therapy retained in RCP and / or proton therapy technical staff (Caen site) * Patient aged 18 or over * Patient affiliated to a social security scheme * Signature of informed consent before any specific procedure related to the study Exclusion Criteria: * History of brain or face irradiation. * Implant or foreign body that can alter MRI imaging. * Contraindication to MRI (pace maker, claustrophobia ...) - Hypersensitivity to gadoteric acid, to meglumine or to any medicine containing gadolinium * Genetic radio sensitizing syndrome * Known neurological comorbidities (stroke, Parkinson's, etc.) that may impact MRI data. * Simultaneous participation in a therapeutic clinical trial * Patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons * Pregnant or breastfeeding women * Persons deprived of their liberty (see article L 1121-6 CSP), * Adults who are the subject of a legal protection measure or unable to express their consent (see article L 1121-8)

Locations (1)

Centre François Baclesse

Caen, France

Outcomes

Primary Outcomes

Evaluate by TESLA multiparametric 3 MRI the modifications of the MRI signal :Change from Baseline at 1, 3 and 6 months

modifications of the MRI signal on the various sequences carried out, during the study

Time frame: Up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.